Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma

References

• Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703–1714. doi:10.1182/blood-2018-11-881268
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229–1253.
   PubMed Web of Science ®Google Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised international society for cutaneous lymphomas/European organisation for research and treatment of cancer staging proposal. J Clin Oncol. 2010;28(31):4730–4739. doi:10.1200/JCO.2009.27.7665
   PubMed Web of Science ®Google Scholar
• Tensen CP, Quint KD, Vermeer MH. Genetic and epigenetic insights into cutaneous T-cell lymphoma. Blood. 2022;139(1):15–33. doi:10.1182/blood.2019004256
   PubMed Web of Science ®Google Scholar
• Dummer R, Vermeer MH, Scarisbrick JJ, et al. Cutaneous T cell lymphoma. Nat Rev Dis Primers. 2021;7(1):61. doi:10.1038/s41572-021-00296-9
   PubMed Web of Science ®Google Scholar
• Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sezary syndrome. Blood. 2016;127(25):3142–3153. doi:10.1182/blood-2015-12-611830
   PubMed Web of Science ®Google Scholar
• Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sezary syndrome. Hematology Am Soc Hematol Educ Program. 2015;2015:529–544. doi:10.1182/asheducation-2015.1.529
   PubMedGoogle Scholar
• Khodadoust MS, Mou E, Kim YH. Integrating novel agents into the treatment of advanced mycosis fungoides and Sezary syndrome. Blood. 2023;141(7):695–703. doi:10.1182/blood.2020008241
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whittaker S, Willemze R, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022;140(5):419–437. doi:10.1182/blood.2021012057
   PubMed Web of Science ®Google Scholar
• Mehta-Shah N, Horwitz SM, Ansell S, et al. NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020. J Natl Compr Canc Netw. 2020;18(5):522–536. doi:10.6004/jnccn.2020.0022
   PubMed Web of Science ®Google Scholar
• Hughes CF, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71–81. doi:10.1182/blood-2014-07-588236
   PubMed Web of Science ®Google Scholar
• Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(1):193–209. doi:10.1002/ajh.26760
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767–771. doi:10.1182/blood-2009-11-251926
   PubMed Web of Science ®Google Scholar
• Roelens M, Delord M, Ram-Wolff C, et al. Circulating and skin-derived Sezary cells: clonal but with phenotypic plasticity. Blood. 2017;130(12):1468–1471. doi:10.1182/blood-2017-03-772996
   PubMed Web of Science ®Google Scholar
• Saleh MN, Kuzel TM, Foss F, et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998;39(1):63–73. doi:10.1016/S0190-9622(98)70403-7
   PubMed Web of Science ®Google Scholar
• Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(11):1870–1877. doi:10.1200/JCO.2009.26.2386
   PubMed Web of Science ®Google Scholar
• Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. Clin Lymphoma Myeloma Leuk. 2013;13(4):377–384. doi:10.1016/j.clml.2013.02.020
   PubMed Web of Science ®Google Scholar
• Kawai H, Ando K, Maruyama D, et al. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. Cancer Sci. 2021;112(6):2426–2435. doi:10.1111/cas.14906
   PubMed Web of Science ®Google Scholar
• Foss FM, Kim YH, Prince HMM, et al. Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with relapsed or refractory cutaneous T-cell lymphoma: results from pivotal study 302. Blood. 2022;140(Supplement 1):1491–1492. doi:10.1182/blood-2022-166916
   Google Scholar
• Prince HMM, Geskin LJ, Akilov OE, et al. Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in patients with relapsed or refractory cutaneous T-cell lymphoma: results from pivotal study 302. Blood. 2022;140(Supplement 1):6577–6578. doi:10.1182/blood-2022-167564
   Google Scholar
• Keating MJ, Jain V, Binet JL, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554–35561. doi:10.1182/blood.V99.10.3554
   PubMed Web of Science ®Google Scholar
• Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101(11):4267–4272. doi:10.1182/blood-2002-09-2802
   PubMed Web of Science ®Google Scholar
• Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol. 2009;144(6):818–831. doi:10.1111/j.1365-2141.2008.07557.x
   PubMed Web of Science ®Google Scholar
• Heit W, Bunjes D, Wiesneth M, et al. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br J Haematol. 1986;64(3):479–486. doi:10.1111/j.1365-2141.1986.tb02203.x
   PubMed Web of Science ®Google Scholar
• de Masson A, Guitera P, Brice P, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol. 2014;170(3):720–724. doi:10.1111/bjd.12690
   PubMed Web of Science ®Google Scholar
• Bernengo MG, Comessatti A, Ortoncelli M, Novelli M, Lisa F, Fierro MT. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007;92(6):784–794. doi:10.3324/haematol.11127
   PubMed Web of Science ®Google Scholar
• Jones D, O’Hara C, Kraus MD, et al. Expression pattern of T-cell–associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood. 2000;96(2):685–690. doi:10.1182/blood.V96.2.685
   PubMed Web of Science ®Google Scholar
• Kallinich T, Muche JM, Qin S, Sterry W, Audring H, Kroczek RA. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol. 2003;121(5):1045–1052. doi:10.1046/j.1523-1747.2003.12555.x
   PubMed Web of Science ®Google Scholar
• Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16(5):1520–1531. doi:10.1158/1078-0432.CCR-09-2697
   PubMed Web of Science ®Google Scholar
• Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. Onco Targets Ther. 2019;12:1085–1094. doi:10.2147/OTT.S165615
   PubMed Web of Science ®Google Scholar
• Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883–1889. doi:10.1182/blood-2014-09-600924
   PubMed Web of Science ®Google Scholar
• Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–1204. doi:10.1016/S1470-2045(18)30379-6
   PubMed Web of Science ®Google Scholar
• Beygi S, Duran GE, Fernandez-Pol S, Rook AH, Kim YH, Khodadoust MS. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma. Blood. 2022;139(26):3732–3736. doi:10.1182/blood.2021014468
   PubMed Web of Science ®Google Scholar
• Roelens M, de Masson A, Andrillon A, et al. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sezary syndrome. Br J Dermatol. 2022;186(6):1010–1025. doi:10.1111/bjd.21018
   PubMed Web of Science ®Google Scholar
• Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation Anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426–3433. doi:10.1200/JCO.2016.67.8250
   PubMed Web of Science ®Google Scholar
• Dai J, Almazan TH, Hong EK, et al. Potential association of anti-CCR4 antibody mogamulizumab and graft-vs-host disease in patients with mycosis fungoides and sezary syndrome. JAMA Dermatol. 2018;154(6):728–730. doi:10.1001/jamadermatol.2018.0884
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–2189. doi:10.1200/JCO.2011.38.0410
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–2196. doi:10.1200/JCO.2011.38.0402
   PubMed Web of Science ®Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2018;378(4):331–344. doi:10.1056/NEJMoa1708984
   PubMed Web of Science ®Google Scholar
• Horwitz S, O’Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–240. doi:10.1016/S0140-6736(18)32984-2
   PubMed Web of Science ®Google Scholar
• Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. Cd30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49(6):1049–1058. doi:10.1016/S0190-9622(03)02484-8
   PubMed Web of Science ®Google Scholar
• Duvic M, Reddy SA, Pinter-Brown L, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009;15(19):6217–6224. doi:10.1158/1078-0432.CCR-09-0162
   PubMed Web of Science ®Google Scholar
• Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–3765. doi:10.1200/JCO.2014.60.3787
   PubMed Web of Science ®Google Scholar
• Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–3758. doi:10.1200/JCO.2014.60.3969
   PubMed Web of Science ®Google Scholar
• Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566. doi:10.1016/S0140-6736(17)31266-7
   PubMed Web of Science ®Google Scholar
• Muniesa C, Gallardo F, Garcia-Doval I, et al. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish primary cutaneous lymphoma registry. J Eur Acad Dermatol Venereol. 2023;37(1):57–64. doi:10.1111/jdv.18563
   PubMed Web of Science ®Google Scholar
• Papadavid E, Kapniari E, Pappa V, et al. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sezary syndrome with variable CD30 positivity. Br J Dermatol. 2021;185(5):1035–1044. doi:10.1111/bjd.20588
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Haun PL, Samimi SS, et al. Brentuximab vedotin for relapsed or refractory sezary syndrome. JAMA Dermatol. 2021;157(3):317–321. doi:10.1001/jamadermatol.2020.4901
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319. doi:10.1056/NEJMoa1411087
   PubMed Web of Science ®Google Scholar
• Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37(34):3291–3299. doi:10.1200/JCO.19.01389
   PubMed Web of Science ®Google Scholar
• Ansell SM. Where do programmed death-1 inhibitors fit in the management of malignant lymphoma? J Oncol Pract. 2016;12(2):101–106. doi:10.1200/JOP.2015.009191
   PubMed Web of Science ®Google Scholar
• Kline J, Godfrey J, Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020;135(8):523–533. doi:10.1182/blood.2019000847
   PubMed Web of Science ®Google Scholar
• Park J, Daniels J, Wartewig T, et al. Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity. Blood. 2021;138(14):1225–1236. doi:10.1182/blood.2020009655
   PubMed Web of Science ®Google Scholar
• Neuwelt A, Al-Juhaishi T, Davila E, Haverkos B. Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas. Blood Adv. 2020;4(17):4256–4266. doi:10.1182/bloodadvances.2020001966
   PubMed Web of Science ®Google Scholar
• Rauch DA, Conlon KC, Janakiram M, et al. Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. Blood. 2019;134(17):1406–1414. doi:10.1182/blood.2019002038
   PubMed Web of Science ®Google Scholar
• Cetinozman F, Jansen PM, Vermeer MH, Willemze R. Differential expression of programmed death-1 (PD-1) in Sezary syndrome and mycosis fungoides. Arch Dermatol. 2012;148(12):1379–1385. doi:10.1001/archdermatol.2012.2089
   PubMed Web of Science ®Google Scholar
• Samimi S, Benoit B, Evans K, et al. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol. 2010;146(12):1382–1388. doi:10.1001/archdermatol.2010.200
   PubMedGoogle Scholar
• Wang L, Ni X, Covington KR, et al. Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet. 2015;47(12):1426–1434. doi:10.1038/ng.3444
   PubMed Web of Science ®Google Scholar
• Saulite I, Ignatova D, Chang YT, et al. Blockade of programmed cell death protein 1 (PD-1) in Sezary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. Oncoimmunology. 2020;9(1):1738797. doi:10.1080/2162402X.2020.1738797
   PubMed Web of Science ®Google Scholar
• Gao Y, Hu S, Li R, et al. Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment. JCI Insight. 2023;8(4). doi:10.1172/jci.insight.164793
   Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase ib study. J Clin Oncol. 2016;34(23):2698–2704. doi:10.1200/JCO.2015.65.9789
   PubMed Web of Science ®Google Scholar
• Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and sezary syndrome: a multicenter phase II study. J Clin Oncol. 2020;38(1):20–28. doi:10.1200/JCO.19.01056
   PubMed Web of Science ®Google Scholar
• Su T, Duran GE, Kwang AC, et al. Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sezary syndrome. Oncoimmunology. 2022;11(1):2115197. doi:10.1080/2162402X.2022.2115197
   PubMed Web of Science ®Google Scholar
• Bachy E, Savage KJ, Huang H, et al. Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: results from a phase 2 study. J Clin Oncol. 2022;40(16_suppl):7552. doi:10.1200/JCO.2022.40.16_suppl.7552
   Web of Science ®Google Scholar
• Querfeld C, Leung S, Myskowski PL, et al. Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile. Cancer Immunol Res. 2018;6(8):900–909. doi:10.1158/2326-6066.CIR-17-0270
   PubMed Web of Science ®Google Scholar
• Beygi S, Fernandez-Pol S, Duran G, et al. Pembrolizumab in mycosis fungoides with PD-L1 structural variants. Blood Adv. 2021;5(3):771–774. doi:10.1182/bloodadvances.2020002371
   PubMed Web of Science ®Google Scholar
• Stadler R, Romero PO, Bagot M, et al. Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb–IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT). Eur J Cancer. 2021;156:S22–S23. doi:10.1016/S0959-8049(21)00668-7
   PubMed Web of Science ®Google Scholar
• Vergnolle I, Douat-Beyries C, Boulinguez S, et al. CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome. Blood Adv. 2022;6(6):1813–1825. doi:10.1182/bloodadvances.2021005147
   PubMed Web of Science ®Google Scholar
• Moins-Teisserenc H, Daubord M, Clave E, et al. CD158k is a reliable marker for diagnosis of Sezary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells. J Invest Dermatol. 2015;135(1):247–257. doi:10.1038/jid.2014.356
   PubMed Web of Science ®Google Scholar
• Van Der Weyden C, Bagot M, Neeson P, Darcy PK, Prince HM. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2018;27(8):691–697. doi:10.1080/13543784.2018.1498081
   PubMed Web of Science ®Google Scholar
• Marie-Cardine A, Viaud N, Thonnart N, et al. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res. 2014;74(21):6060–6070. doi:10.1158/0008-5472.CAN-14-1456
   PubMed Web of Science ®Google Scholar
• Bagot M, Porcu P, Marie-Cardine A, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019;20(8):1160–1170. doi:10.1016/S1470-2045(19)30320-1
   PubMed Web of Science ®Google Scholar
• Bagot M, Kim YH, Ortiz-Romero PL, et al. Lacutamab in patients with advanced sezary syndrome: results from an interim analysis of the tellomak phase 2 trial. Blood. 2022;140(Supplement 1):3760–3761. doi:10.1182/blood-2022-160239
   Google Scholar
• Kamijo H, Miyagaki T, Takahashi-Shishido N, et al. Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47. Leukemia. 2020;34(3):845–856. doi:10.1038/s41375-019-0622-6
   PubMed Web of Science ®Google Scholar
• Johnson LDS, Banerjee S, Kruglov O, et al. Targeting CD47 in Sezary syndrome with SIRPalphaFc. Blood Adv. 2019;3(7):1145–1153. doi:10.1182/bloodadvances.2018030577
   PubMed Web of Science ®Google Scholar
• Ansell SM, Maris MB, Lesokhin AM, et al. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2021;27(8):2190–2199. doi:10.1158/1078-0432.CCR-20-3706
   PubMed Web of Science ®Google Scholar
• Patel K, Orlowski RZ, Doucette K, et al. TTI-622-01: a phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma. J Clin Oncol. 2022;40(16_suppl):TPS8071–TPS8071. doi:10.1200/JCO.2022.40.16_suppl.TPS8071
   Google Scholar
• Patel K, Zonder JA, Sano D, et al. CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: update from the ongoing first-in-human dose escalation study. Blood. 2021;138(Supplement 1):3560. doi:10.1182/blood-2021-153683
   Google Scholar
• Han Z, Wu X, Yuan Y-C, et al. Blockade of the immune checkpoint CD47 By TTI-621 potentiates the response to anti-PD-L1 in cutaneous T cell lymphoma. Blood. 2022;140(Supplement 1):6376–6377. doi:10.1182/blood-2022-167670
   Google Scholar
• Querfeld C, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood. 2014;123(8):1159–1166. doi:10.1182/blood-2013-09-525915
   PubMed Web of Science ®Google Scholar
• Querfeld C, Tsai N-C, Palmer J, et al. Phase 1 results of anti-PD-Ligand 1 (Durvalumab) & lenalidomide in patients with cutaneous T cell lymphoma and correlation with programmed death ligand 1 expression and gene expression profile. Blood. 2020;136(Supplement 1):20. doi:10.1182/blood-2020-143354
   Google Scholar
• Amatore F, Ortonne N, Lopez M, et al. ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. Blood Adv. 2020;4(20):5203–5214. doi:10.1182/bloodadvances.2020002395
   PubMed Web of Science ®Google Scholar
• Anzengruber F, Ignatova D, Schlaepfer T, et al. Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndrome. Leuk Lymphoma. 2019;60(8):1899–1907. doi:10.1080/10428194.2018.1564827
   PubMed Web of Science ®Google Scholar
• Leupin N, Zinzani PL, Morschhauser F, et al. Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma. Cancer. 2022;128(5):1004–1014. doi:10.1002/cncr.34005
   PubMed Web of Science ®Google Scholar
• Isabelle C, McConnell K, Boles AE, et al. Therapeutic potential and role of CD38 in cutaneous T-cell lymphoma pathogenesis. Blood. 2022;140(Supplement 1):9216–9218. doi:10.1182/blood-2022-170550
   Google Scholar
• Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007;109(11):4655–4662. doi:10.1182/blood-2006-12-062877
   PubMed Web of Science ®Google Scholar
• Mohty M, Gautier J, Malard F, et al. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia. 2019;33(12):2767–2778. doi:10.1038/s41375-019-0615-5
   PubMed Web of Science ®Google Scholar
• To V, Evtimov VJ, Jenkin G, Pupovac A, Trounson AO, Boyd RL. CAR-T cell development for cutaneous T cell lymphoma: current limitations and potential treatment strategies. Front Immunol. 2022;13:968395. doi:10.3389/fimmu.2022.968395
   PubMed Web of Science ®Google Scholar
• Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. 2023;141(8):856–868. doi:10.1182/blood.2022016200
   PubMed Web of Science ®Google Scholar
• Qasim W. Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells. Blood. 2023;141(8):835–845. doi:10.1182/blood.2022016204
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li C, Jiang H, et al. Allogeneic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T cell malignancies. Blood. 2022;140(Supplement 1):4592–4594. doi:10.1182/blood-2022-170819
   Google Scholar
• Iyer SP, Sica RA, Ho PJ, et al. S262: the Cobalt-Lym study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered car T cells in patients with relapsed/refractory (r/r) T-cell malignancies. HemaSphere. 2022;6:163–164. doi:10.1097/01.HS9.0000843940.96598.e2
   Google Scholar
• Frigault MJ, Chen Y-B, Gallagher KME, et al. Phase 1 Study of CD37-Directed CAR T cells in patients with relapsed or refractory CD37+ Hematologic malignancies. Blood. 2021;138(Supplement 1):653. doi:10.1182/blood-2021-146236
   Google Scholar
• Watanabe K, Aznar MA, Kuramitsu S, et al. Identifying highly active anti-CCR4-CAR T cells for the treatment of T-cell lymphoma. Blood Adv. 2023;7:3416–3430. doi:10.1182/bloodadvances.2022008327
   PubMed Web of Science ®Google Scholar
• Atilla PA, Atilla E. Are we there yet? Cellular therapies for cutaneous T cell lymphoma. Curr Res Transl Med. 2023;71(2):103390. doi:10.1016/j.retram.2023.103390
   PubMed Web of Science ®Google Scholar
• Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183–1194. doi:10.1182/blood-2017-10-811224
   PubMed Web of Science ®Google Scholar
• Hong DS, Rixe O, Chiu VK, et al. Mogamulizumab in Combination with Nivolumab in a Phase I/II study of patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2022;28(3):479–488. doi:10.1158/1078-0432.CCR-21-2781
   PubMed Web of Science ®Google Scholar